Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center AstraZeneca |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00290537 |
The goal of this clinical research study is to learn how the drug ZD6474 affects the amount of tumor cell death in the body and the amount of blood that can be supplied to the tumor. The safety of ZD6474 alone and when given with chemotherapy will be studied. In addition, the side effects and response to this treatment will also be studied.
Condition | Intervention | Phase |
---|---|---|
Lung Cancer |
Drug: ZD6474 Drug: Carboplatin Drug: Paclitaxel |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Study of ZD6474 Alone and With Chemotherapy in Advanced NSCLC |
Enrollment: | 5 |
Study Start Date: | January 2006 |
Study Completion Date: | April 2008 |
Primary Completion Date: | June 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
The first part of the protocol treatment will be three 3-week cycles. During each 21-day cycle patients will be given 300 mg of ZD6474 daily. In the second part of the study, patients will be randomized to receive either: 1) 300 mg of ZD6474 daily, or 2) 100 mg of ZD6474 daily plus carboplatin and paclitaxel every 3 weeks. Patients randomized to receive carboplatin and paclitaxel will receive paclitaxel 200 mg/m2 intravenous (iv) over 3 hours on Day 1, immediately followed by carboplatin AUC 6.0 iv over 15-30 minutes, repeated in cycles of 3 weeks for up to 6 cycles or until disease progression, whichever comes first.
|
Drug: ZD6474
Arm 1, Cycles 1-3 = 300 mg PO Daily x 3 Weeks; Arm 2 = 300 mg PO Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.
|
2: Active Comparator
The first part of the protocol treatment will be three 3-week cycles. During each 21-day cycle patients will be given 300 mg of ZD6474 daily. In the second part of the study, patients will be randomized to receive either: 1) 300 mg of ZD6474 daily, or 2) 100 mg of ZD6474 daily plus carboplatin and paclitaxel every 3 weeks.
|
Drug: ZD6474
Arm 1, Cycles 1-3 = 300 mg PO Daily x 3 Weeks; Arm 2 = 300 mg PO Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.
Drug: Carboplatin
6 AUC IV Over 15-30 Minutes, Immediately After Paclitaxel
Drug: Paclitaxel
200 mg/m2 IV Over 3 Hours On Day 1
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients must have adequate hepatic, renal, and bone marrow function as defined below: 1) Serum creatinine < 1.5 mg/dL or a calculated creatinine clearance > 60 mL/min 2)· Total bilirubin < 1.5 x ULN ·3) ALT or AST </= 2.5 x ULN OR ALT or AST </= 5.0 x ULN if related to liver metastases OR Alk Phos </= 2.5 x ULN ·4) WBC > 3,000/mm**3 ·5) ANC > 1,500 mm**3 ·6) Platelets > 100,000/mm**3 ·7) Hemoglobin > 10 g/dL
Exclusion Criteria:
United States, Texas | |
University of Texas M.D.Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Vassiliki Papadimitrakopoulou, M.D. | M.D. Anderson Cancer Center |
Responsible Party: | University of Texas M.D. Anderson Cancer Center ( Vassiliki Papadimitrakopoulou, M.D./Associate Professor ) |
Study ID Numbers: | 2003-0635 |
Study First Received: | February 10, 2006 |
Last Updated: | April 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00290537 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Non-Small Cell Lung Cancer Lung Cancer Carboplatin |
Paclitaxel ZD6474 NSCLC |
Thoracic Neoplasms Respiratory Tract Diseases Paclitaxel Lung Neoplasms Lung Diseases Tubulin Modulators |
Non-small Cell Lung Cancer Antimitotic Agents Carboplatin Antineoplastic Agents, Phytogenic Carcinoma, Non-Small-Cell Lung |
Thoracic Neoplasms Respiratory Tract Neoplasms Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Mitosis Modulators Antimitotic Agents Carboplatin Pharmacologic Actions Neoplasms |
Neoplasms by Site Respiratory Tract Diseases Lung Neoplasms Paclitaxel Lung Diseases Therapeutic Uses Tubulin Modulators Antineoplastic Agents, Phytogenic |